Another example is crizotinib, a first-generation ALK inhibitor, which was approved by the FDA in January, 2021 for treating pediatric and young adult patients with relapsed or refractory ALK+ ALCL [38]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.